Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Higano CS, Krieger LE, Sternberg CN, Watkins SP, Despain D, Simmons AD, Loehr A, Dowson M, Golsorkhi T, Chowdhury S; TRITON2 investigators.J
[Treatment of metastatic, castration-resistant prostate cancer].
von Amsberg G, Merseburger AS.Urologe A. 2020 Jun;59(6):673-679. doi: 10.1007/s00120-020-01187-9.PMID: 32274540
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.
Abida W, Campbell D, Patnaik A, Shapiro JD, Sautois B, Vogelzang NJ, Voog EG, Bryce AH, McDermott R, Ricci F, Rowe J, Zhang J, Piulats JM, Fizazi K, Merseburger AS, Higano CS, Krieger LE, Ryan CJ, Feng FY, Simmons AD, Loehr A, Despain D, Dowson M, Green F, Watkins SP, Golsorkhi T, Chowdhury S.Clin Cancer Res. 2020 Jun 1;26(11):2487-2496. doi: 10.1158/1078-0432.CCR-20-0394. Epub 2020 Feb 21.PMID: 32086346
[mHSPC-Therapie mit Apalutamid/ADT].
Bismarck E, Hammerer P, Merseburger AS, Schrader AJ.Oncol Res Treat. 2020;43 Suppl 2:6-12. doi: 10.1159/000507054. Epub 2020 May 20.PMID: 32434198
Perioperativer Einsatz von Pembrolizumab bei muskelinvasivem Blasenkarzinom.
Rexer H, Bedke J, Merseburger A.Aktuelle Urol. 2020 Sep;51(5):418-420. doi: 10.1055/a-1177-3856. Epub 2020 Aug 26.PMID: 32846453 German.
Erratum zu: Thromboserate und Blutungen in der universitären operativen Urologie unter standardisierter Antikoagulation.
Morische SK, Kramer MW, Merseburger AS, Gieseler F, Cordes J.Urologe A. 2020 Jan;59(1):52. doi: 10.1007/s00120-019-01081-z.PMID: 31919560 German
Kombinierte Strahlen-Immuntherapie beim lokal fortgeschrittenen Blasenkarzinom.
Rexer H, Schmid S, Merseburger A.Aktuelle Urol. 2020 Apr;51(2):101-102. doi: 10.1055/a-1017-4964. Epub 2020 Mar 24.PMID: 32208509
Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized controlled trials.
Laukhtina E, Mori K, Mostafaei H, Merseburger AS, Nyirady P, Moschini M, Quhal F, Pradere B, Motlagh RS, Enikeev D, Shariat SF; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU).Semin Oncol. 2021 Jun;48(3):181-192. doi: 10.1053/j.seminoncol.2021.09.005. Epub 2021 Oct 2.PMID: 34749886
Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer.
Frantzi M, Hupe MC, Merseburger AS, Schanstra JP, Mischak H, Latosinska A.Diagnostics (Basel). 2020 Aug 31;10(9):658. doi: 10.3390/diagnostics10090658.PMID: 32878288
[Treatment of oligo- and advanced metastatic prostate cancer].
Hadaschik BA, Merseburger AS.Urologe A. 2020 Jun;59(6):657-658. doi: 10.1007/s00120-020-01197-7.PMID: 32519055
[Prostate cancer - where is the journey going?].
Merseburger A.Aktuelle Urol. 2020 Dec;51(6):545-546. doi: 10.1055/a-1220-0608. Epub 2020 Nov 24.PMID: 33233001 German.
Histomorphological analysis of false positive PI-RADS 4 and 5 lesions.
Hupe MC, Offermann A, Tharun L, Fürschke A, Frydrychowicz A, Garstka N, Shariat SF, Barkhausen J, Merseburger AS, Kramer MW, Perner S.Urol Oncol. 2020 Jul;38(7):636.e7-636.e12. doi: 10.1016/j.urolonc.2020.01.017. Epub 2020 Feb 27.PMID: 32113858
Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer.
Becker F, Joerg V, Hupe MC, Roth D, Krupar R, Lubczyk V, Kuefer R, Sailer V, Duensing S, Kirfel J, Merseburger AS, Brägelmann J, Perner S, Offermann A.Int J Cancer. 2020 Jan 15;146(2):577-588. doi: 10.1002/ijc.32551. Epub 2019 Jul 19.PMID: 31271443
Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma.
Bedke J, Merseburger AS, Loriot Y, Castellano D, Choy E, Duran I, Rosenberg JE, Petrylak DP, Dreicer R, Perez-Gracia JL, Hoffman-Censits JH, Van Der Heijden MS, Pavlova J, Thiebach L, de Ducla S, Fear S, Powles T, Sternberg CN.Eur Urol Focus. 2021 Sep;7(5):1084-1091. doi: 10.1016/j.euf.2020.10.009. Epub 2020 Nov 6.PMID: 33168461
[Rate of thrombosis and bleeding after urological surgery under standardized anticoagulation].
Morische SK, Kramer MW, Merseburger AS, Gieseler F, Cordes J.Urologe A. 2020 Jan;59(1):40-51. doi: 10.1007/s00120-019-01045-3.PMID: 31541268 German.
Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA.
Morera DS, Hasanali SL, Belew D, Ghosh S, Klaassen Z, Jordan AR, Wang J, Terris MK, Bollag RJ, Merseburger AS, Stenzl A, Soloway MS, Lokeshwar VB.J Urol. 2020 Jan;203(1):62-72. doi: 10.1097/JU.0000000000000351. Epub 2019 May 21.PMID: 31112107
Hemopatch® as a Hemostatic Agent is Safe in Partial Nephrectomy: A Large, Single-Surgeon Retrospective Evaluation.
Hupe MC, Büttner M, Tabrizi PF, Merseburger AS, Kuczyk MA, Imkamp F.Adv Ther. 2021 Feb;38(2):1024-1034. doi: 10.1007/s12325-020-01584-8. Epub 2020 Dec 4.PMID: 33277680
[Reports of prostate needle biopsies-what pathologists provide and urologists want].
Offermann A, Hupe MC, Joerg V, Sailer V, Kramer MW, Merseburger AS, Tharun L, Perner S.Urologe A. 2020 Apr;59(4):461-468. doi: 10.1007/s00120-020-01121-z.PMID: 32016505 German.
Bicentric Retrospective Analysis of en Bloc Resection and Muscularis Mucosae Detection Rate in Non-Muscle Invasive Bladder Tumors: A Real-World Scenario.
Struck JP, Kramer MW, Katzendorn O, Hupe MC, Ozimek T, Hennig MJP, Wießmeyer JR, von Klot CAJ, Kuczyk MA, Kreipe HH, Merseburger AS, Perner S, Dressler FF.Adv Ther. 2021 Jan;38(1):258-267. doi: 10.1007/s12325-020-01529-1. Epub 2020 Oct 22.PMID: 33094476
Impact of COVID-19 crisis on medical care of patients with metastasized uro-oncologic disease under systemic cancer therapy: a multicenter study in German university hospitals.
Struck JP, Schnoor M, Schulze A, Hupe MC, Ozimek T, Oppolzer IA, Schnabel MJ, Burger M, Darr C, Gruenwald V, Hadaschik B, Weinke M, Kuebler H, Klockenbusch JC, Grabbert MT, Gratzke C, Kramer MW, Katalinic A, Merseburger AS.World J Urol. 2021 Nov 30:1-10. doi: 10.1007/s00345-021-03868-2.
[The impact of the androgen receptor splice variant AR-V7 on the prognosis and treatment of advanced prostate cancer].
Thelen P, Taubert H, Duensing S, Kristiansen G, Merseburger AS, Cronauer MV.Aktuelle Urol. 2020 Dec;51(6):582-592. doi: 10.1055/s-0043-115426. Epub 2018 Jan 25.PMID: 29370587
[Olaparib for metastatic prostate cancer-the PROfound trial].
Merseburger AS.Urologe A. 2020 Oct;59(10):1249-1250. doi: 10.1007/s00120-020-01306-6.PMID: 32785732
Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel.
Fernández-Pello S, Hora M, Kuusk T, Tahbaz R, Dabestani S, Abu-Ghanem Y, Albiges L, Giles RH, Hofmann F, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Powles T, Staehler M, Volpe A, Ljungberg B, Bex A, Bensalah K.Eur Urol Oncol. 2020 Feb;3(1):57-72. doi: 10.1016/j.euo.2019.04.005. Epub 2019 Jun 4.PMID: 31171501
Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts.
Elghazaly H, Mottet N, Garcia J, Oudard S, Roach M, Abbou C, Merseburger A, Emara A, Shehata S, Tawfik H, Khorshid O, Selim A, Assem A, Abdelkarim K, Ezz El-Arab L, Bazarbashi S, Omar A, Elwakil H, Elashry M, Abou ElFotouh M, Osman T, Ezz El Din M.World J Urol. 2021 May;39(5):1421-1429. doi: 10.1007/s00345-020-03328-3. Epub 2020 Jul 8.PMID: 32643031
[Utility Analysis of Oncological Centre Building in the Field of Colorectal Cancer].
Weinhold I, Keck T, Merseburger A, Rody A, Wollenberg B, Wende D, Häckl D, Elsner C.Zentralbl Chir. 2018 Apr;143(2):181-192. doi: 10.1055/s-0042-122854. Epub 2017 May 4.PMID: 28472845
[TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)].
Merseburger AS, Suttmann H.Aktuelle Urol. 2021 Apr;52(2):155-160. doi: 10.1055/a-1076-3036. Epub 2020 Oct 28.PMID: 33113571
[Changes in the treatment of metastatic prostate cancer-new data and open questions].
Albers P, Bögemann M, Machtens S, Merseburger AS, Schostak M, Steuber T, Wülfing C, De Santis M.Urologe A. 2020 Mar;59(3):307-317. doi: 10.1007/s00120-019-01072-0.PMID: 31781782
New computed tomographic predictors of complicated perioperative course of 17.5F mini-percutaneous nephrolithotomy (mini-PNL).
Ozimek T, Laturnus JM, Gohlke C, Wiessmeyer JR, Struck JP, Hupe MC, Merseburger AS, Kramer MW.World J Urol. 2021 Jun;39(6):2147-2154. doi: 10.1007/s00345-020-03388-5. Epub 2020 Aug 9.PMID: 32772148
[Retrospective SHI (Statutory Health Insurances) real-world study on initial GnRH antagonist and agonist therapy for advanced prostate cancer: prescription patterns and hospital costs in Germany].
Hupe MC, Hammerer P, Ketz M, Kossack N, Colling C, Merseburger AS.Aktuelle Urol. 2020 Jun;51(3):275-284. doi: 10.1055/a-1018-1651. Epub 2019 Nov 19.PMID: 31745962
[A retrospective comparison of robotic assisted and conventional laparoscopic pyeloplasty in two centres].
Griessner H, Oberhammer L, Pallauf M, Oswald D, Kunit T, Colleselli D, Merseburger A, Kramer M, Lusuardi L, Mitterberger M.Urologe A. 2021 Apr;60(4):491-495. doi: 10.1007/s00120-020-01414-3. Epub 2020 Dec 8.PMID: 33294939
[CARD study: relevance for the treatment of advanced prostate cancer].
Merseburger AS, Bannowsky A, Becker K, Bokemeyer C, Eichenauer R, Lehmann J, Mickisch G, Steuber T, von Amsberg G, von Kügelgen T, Wülfing C.Aktuelle Urol. 2022 Feb;53(1):54-59. doi: 10.1055/a-1247-4155. Epub 2020 Sep 23.PMID:
Why is the principle of "as much radicality as needed, as much organ preservation as possible" only insufficiently implemented in daily practice in the surgical treatment of penile cancer patients?
May M, Rink M, Merseburger AS, Brookman-May SD.Transl Androl Urol. 2020 Oct;9(5):1901-1903. doi: 10.21037/tau-20-1152.PMID: 33209653
A Phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer.
Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, Oudard S, Saad F, Soares A, Benzaghou F, Kerloeguen Y, Kimura A, Mohamed N, Panneerselvam A, Wang F, Pal S.Future Oncol. 2022 Jan 17. doi: 10.2217/fon-2021-1096. Online ahead of print.PMID: 35034502
[Correction: Wnt signaling in cutaneous wound healing].
Houschyar KS, Tapking C, Puladi B, Popp D, Duscher D, Rein S, Reumuth G, Grieb G, Branski LK, Siemers F, Lehnhardt M, Yazdi AS.Handchir Mikrochir Plast Chir. 2020 Apr;52(2):E1. doi: 10.1055/a-1072-9912. Epub 2019 Dec 3.PMID: 31797344
The Impact of Endourological Experience on Flexible Ureteroscopy Outcomes and Performance at Different Levels of Expertise: Retrospective Multifactorial Analysis.
Ozimek T, Kramer MW, Hupe MC, Laturnus JM, Struck JP, Hennig MJP, Merseburger AS, Cordes J.Urol Int. 2020;104(5-6):452-458. doi: 10.1159/000504989. Epub 2020 Feb 25.PMID: 32097920
Adherence to the EAU Guideline Recommendations for Local Tumor Treatment in Penile Cancer: Results of the European PROspective Penile Cancer Study Group Survey (E-PROPS).
Pallauf M, Hempel MC, Hupe MC, May M, Haccius M, Weckermann D, Lebentrau S, Hoschke B, Necknig U, Pfitzenmaier J, Manka L, Nuhn P, Törzsök P, Lusuardi L, Merseburger AS.Adv Ther. 2020 Dec;37(12):4969-4980. doi: 10.1007/s12325-020-01514-8. Epub 2020 Oct 10.PMID: 33038006
Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel.
Abu-Ghanem Y, Fernández-Pello S, Bex A, Ljungberg B, Albiges L, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Kuusk T, Marconi L, Merseburger AS, Tahbaz R, Staehler M, Volpe A, Powles T, Lam TB, Bensalah K.Eur Urol Oncol. 2020 Aug;3(4):433-452. doi: 10.1016/j.euo.2020.02.001. Epub 2020 Mar 31.PMID: 32245655
Progressive instability of bilateral sacral fragility fractures in osteoporotic bone: a retrospective analysis of X-ray, CT, and MRI datasets from 78 cases.
Mendel T, Ullrich BW, Hofmann GO, Schenk P, Goehre F, Schwan S, Klauke F.Eur J Trauma Emerg Surg. 2021 Feb;47(1):11-19. doi: 10.1007/s00068-020-01480-4. Epub 2020 Sep 2.PMID: 32876773
The new ISUP 2014/WHO 2016 prostate cancer grade group system: first résumé 5 years after introduction and systemic review of the literature.
Offermann A, Hupe MC, Sailer V, Merseburger AS, Perner S.World J Urol. 2020 Mar;38(3):657-662. doi: 10.1007/s00345-019-02744-4. Epub 2019 Apr 2.PMID: 30941561
Nomograms including the UBC® Rapid test to detect primary bladder cancer based on a multicentre dataset.
Meisl CJ, Karakiewicz PI, Einarsson R, Koch S, Hallmann S, Weiß S, Hemdan T, Malmström PU, Styrke J, Sherif A, Hasan MN, Pichler R, Tulchiner G, Palou J, Rodríguez Faba Ó, Hennenlotter J, Stenzl A, Ritter R, Niegisch G, Grunewald CM, Schlomm T, Friedersdorff F, Barski D, Otto T, Gössl A, Arndt C, Esuvaranathan K, Kesavan NR, Zhijiang Z, Kramer MW, Hennig MJP, Ecke TH.BJU Int. 2021 Dec 20. doi: 10.1111/bju.15677. Online ahead of print.PMID: 34928524
[Immuno-oncological therapeutic options in high-risk non-muscle invasive bladder cancer].
Kramer MW, Gakis G.Urologe A. 2020 Jul;59(7):784-789. doi: 10.1007/s00120-020-01233-6.PMID: 32468091 Review. German.
[Current practice patterns of perioperative cystectomy management in Germany: a questionnaire survey].
Dressler FF, Dogan S, Hennig M, Frank T, Struck J, Cebulla A, Salem J, Borgmann H, Klatte T, Kramer MW, Hofbauer S.Aktuelle Urol. 2021 Feb;52(1):82-87. doi: 10.1055/a-1025-2523. Epub 2020 Jul 29.PMID: 32726815 German.
[Rapid Progress in the treatment of bladder cancer: recent achievements].
Kramer MW, Bolenz C.Aktuelle Urol. 2020 Aug;51(4):342-343. doi: 10.1055/a-1137-1404. Epub 2020 Jul 29.PMID: 32726841 German. No abstract available.
An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting.
Teoh JY, MacLennan S, Chan VW, Miki J, Lee HY, Chiong E, Lee LS, Wei Y, Yuan Y, Yu CP, Chow WK, Poon DM, Chan R, Lai F, Ng CF, Breda A, Kramer MW, Malavaud B, Mostafid H, Herrmann T, Babjuk M.Eur Urol. 2020 Oct;78(4):546-569. doi: 10.1016/j.eururo.2020.04.059. Epub 2020 May 8.PMID: 32389447
[Potential for improvement by new resection and imaging techniques in TUR-B].
Hennig MJP, Kramer MW.Aktuelle Urol. 2020 Aug;51(4):348-352. doi: 10.1055/a-1171-1137. Epub 2020 Jun 10.PMID: 32521550 German.
A Novel Splice Variant of HYAL-4 Drives Malignant Transformation and Predicts Outcome in Patients with Bladder Cancer.
Lokeshwar VB, Morera DS, Hasanali SL, Yates TJ, Hupe MC, Knapp J, Lokeshwar SD, Wang J, Hennig MJP, Baskar R, Escudero DO, Racine RR, Dhir N, Jordan AR, Hoye K, Azih I, Manoharan M, Klaassen Z, Kavuri S, Lopez LE, Ghosh S, Lokeshwar BL.Clin Cancer Res. 2020 Jul 1;26(13):3455-3467. doi: 10.1158/1078-0432.CCR-19-2912. Epub 2020 Feb 24.PMID: 32094233
Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany .
Eisen C, Lulic Z, Palacios-Moreno JM, Adalig B, Hennig M, Cortes V, Gilg F, Kostev K.Int J Clin Pharmacol Ther. 2020 Jan;58(1):37-49. doi: 10.5414/CP203549.PMID: 31670653
Increased Severe Adverse Outcomes and Decreased Emergency Room Visits for Pyelonephritis: First Report of Collateral Damage during COVID-19 Pandemic in Urology.
Borgmann H, Struck JP, Mattigk A, Wenzel M, Pilatz A, Kranz J, Weiten R, von Landenberg N, Spachmann PJ, Aksoy C, Haferkamp A, Boehm K.Urol Int. 2021;105(3-4):199-205. doi: 10.1159/000513458. Epub 2021 Jan 6.PMID: 33406523